Several key companies are active in the therapeutic domain, and the therapies under development are focused on novel approaches to treat the disease. The current advancements in treatment, like the development of adherence-friendly drug formulations, gene therapy, a drug for better treatment of motor symptoms, and emerging pipelines, will significantly impact the Parkinson’s Disease treatment scenario in the coming years.
DelveInsight’s “Parkinson’s Disease Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Parkinson’s Disease Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Parkinson’s Disease market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Parkinson’s Disease: An Overview
Parkinson’s disease (PD) is a progressive disorder that is caused by the degeneration of nerve cells in the part of the brain called the substantia nigra, which controls movement. The cause of Parkinson’s Disease remains unknown, but it has long been hypothesized that exposure to environmental risk factors may be one cause, along with an inherited susceptibility. The majority of cases are thought to arise sporadically, although up to 20% of people with Parkinson’s Disease also have a first-degree relative with Parkinson’s Disease.
There is no standard treatment for Parkinson’s Disease. Treatment for each person with Parkinson’s is based on his or her symptoms. There are many medications available to treat Parkinson’s symptoms, although none yet that reverse the effects of the disease.
The medications used to treat Parkinson’s disease include levodopa dopamine agonists, MAO-B inhibitors, COMT-Inhibitors, amantadine, anticholinergics, and adenosine A2a antagonists.
Parkinson’s Disease Market Key Facts
According to Parkinson’s Foundation, nearly one million people in the US are living with Parkinson’s Disease. This is expected to rise to 1.2 million by 2030. Approximately 60,000 Americans are diagnosed with Parkinson’s Disease each year. Also, men are 1.5 times more likely to have Parkinson’s Disease than women.
According to a study by Balestrino and Schapira (2019), in industrialized countries, the estimated prevalence of Parkinson’s Disease is 0.3% in the general population, 1.0% in people older than 60 years and 3.0% in people older than 80 years. In Europe, the estimated prevalence of Parkinson’s Disease range between 65 and 12,500 per 100 000 person-years.
As per Parkinson’s Foundation, men are 1.5 times more likely to have Parkinson’s disease than women.
Parkinson’s Disease Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Parkinson’s Disease market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report details the Parkinson’s Disease market trend for each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.
Parkinson’s Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.
Parkinson’s Disease Epidemiology Segmentation
Total prevalent cases of Parkinson’s Disease
Gender-specific cases of Parkinson’s Diseas
Stage-specific cases of Parkinson’s Disease
Age-specific cases of Parkinson’s Disease
Cases of Parkinson’s Disease based on Onset
Parkinson’s Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Parkinson’s Disease market or expected to get launched during the study period. The analysis covers Parkinson’s Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Parkinson’s Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Request for Sample PDF Report – https://www.delveinsight.com/sample-request/parkinsons-disease-market-size-analysis-treatment
Parkinson’s Disease Therapeutics Analysis
The current emerging landscape for Parkinson’s Disease is vast, comprising several Phase II and Phase III candidate drugs. The therapies are expected to launch in the coming years. The current Parkinson’s disease market is highly competitive and subject to rapid and significant technological changes.
As per DelveInsight, the launch of newer therapies Atuzaginstat (Cortexyme), Tavapadon (Cerevel Therapeutics), IPX203 (Amneal Pharmaceuticals), P2B001 (Pharma Two B), ND0612 (NeuroDerm/Mitsubishi), and others will fuel the Parkinson’s Disease Therapeutics market.
Some of the Key Companies in the Parkinson’s Disease Market include:
Cortexyme
Cerevel Therapeutics
Amneal Pharmaceuticals
Pharma Two B
Cerevance Beta
And others.
Parkinson’s Disease Therapies covered in the report include:
IPX203
P2B001
CVN424
Atuzaginstat
Tavapadon
And many more.
Get More Detailed Insights Into the Emerging Therapies & Key Companies – https://www.delveinsight.com/sample-request/parkinsons-disease-market-size-analysis-treatment
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Parkinson’s Disease Competitive Intelligence Analysis
4. Parkinson’s Disease Market Overview at a Glance
5. Parkinson’s Disease Disease Background and Overview
6. Parkinson’s Disease Patient Journey
7. Parkinson’s Disease Epidemiology and Patient Population
8. Parkinson’s Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Parkinson’s Disease Unmet Needs
10. Key Endpoints of Parkinson’s Disease Treatment
11. Parkinson’s Disease Marketed Products
12. Parkinson’s Disease Emerging Therapies
13. Parkinson’s Disease Seven Major Market Analysis
14. Attribute Analysis
15. Parkinson’s Disease Market Outlook (7 major markets)
16. Parkinson’s Disease Access and Reimbursement Overview
17. KOL Views on the Parkinson’s Disease Market.
18. Parkinson’s Disease Market Drivers
19. Parkinson’s Disease Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report – https://www.delveinsight.com/sample-request/parkinsons-disease-market-size-analysis-treatment
About DelveInsightDelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Reports by DelveInsight
Atherectomy Devices Market“Atherectomy Devices Market” research report provides comprehensive insights into the historic and forecasted market size, share, trends, and growth estimation for Atherectomy Devices. It also covers the latest breakthroughs, collaboration, latest innovations, emerging devices, and key companies working in the global Atherectomy Devices market.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
